The global Drugs for Treatment of Prostate Cancer market was valued at USD 30.41 Billion in 2015, and is projected to reach USD 35.26 Billion by 2021, at a CAGR of 59.49% between 2016 and 2021. The market is projected witness significant growth in the coming years, owing to the aging population increase, increased incidence and development of new drugs
This report studies Drugs for Treatment of Prostate Cancer in China, Russia, Brazil and Japan market, including Triptorelin, Leuprorelin, Flutamide Tablets, Goserelin, Bicalutamide Tablets, Bicalutamide Capsules, Estramustine Phosphate Capsules, Mitoxantrone, Zytiga and Xtandi, focuses on price, sales, revenue of each type in global. This report also focuses on the sales (consumption), production, import and export of Drugs for Treatment of Prostate Cancer forecast to 2021, from 2015.
On basis of segments by Types, this report focuses on price, sales, revenue and growth rate of each type, as well as the types and each type price of key manufacturers, through interviewing key manufacturers.
On basis of segments by manufacturers, this report focuses on the sales, price of each type, average price of Drugs for Treatment of Prostate Cancer, revenue and market share, for key manufacturers. The main manufacturers as follows: IPSEN, Ferring Pharmaceuticals, Takeda Pharmaceutical Company Limited, Schering-Plough Canada, S.C.SINDAN-PHARMA S.R.L., AstraZeneca, Corden Pharma GmbH, Shanxi Zhendong Pharmaceutical, Pfizer, Johnson, Astellas and so on.
On basis of segments by regions, this report focuses on the sales (consumption), production, import and export of Drugs for Treatment of Prostate Cancer in America, Established ROW, Western Europe, Emerging Markets, Russia and China.
On basis of segments by applications, this report focuses on consumption and growth rate of Drugs for Treatment of Prostate Cancer in major applications.
With 220ges, 231 charts and eight chapters, to display the market present situation and future, clearly and deeply.